Opioid-induced neurotoxicity (OIN) is one of the most important and most mismanaged complications in palliative care — the paradox of pain worsening despite opioid dose escalation is the key diagnostic feature. OIN is caused by accumulation of opioid metabolites (primarily morphine-3-glucuronide, which is pro-nociceptive and neuroexcitatory — it lowers the seizure threshold and sensitises pain pathways rather than blocking them). The clinical features are: pain that worsens with opioid dose increases (opioid-induced hyperalgesia), myoclonus (spontaneous muscle jerking — metabolite-driven CNS excitability), hallucinations, vivid nightmares, cognitive impairment, and occasionally seizures. The treatment is NOT to increase the morphine dose (this worsens OIN) and NOT to give naloxone (this precipitates acute pain crisis and opioid withdrawal). The correct treatment is: opioid rotation to an opioid with a different metabolite profile (fentanyl and oxycodone produce fewer excitatory metabolites than morphine), dose conversion using published equianalgesic tables (adjusted downward by 25–30% for incomplete cross-tolerance), IV/SC hydration to improve metabolite clearance, and renalfunction review (dose reduction in renal impairment). This is a palliative care specialist decision — GPs should recognise the syndrome and phone the specialist team same day. The MSCC (metastatic spinal cord compression) dexamethasone dose of 16 mg/day is the NICE-recommended dose — it must be given immediately on clinical suspicion, before imaging is confirmed, because the window for preserving neurological function closes rapidly. NICE CG75 specifies that any patient with cancer who develops new back pain or neurological symptoms must be assessed for MSCC as a matter of urgency, and dexamethasone started same day.

The concept of 'total pain' is Cicely Saunders's most enduring contribution to palliative medicine — she observed at St Christopher's Hospice that patients with apparently well-controlled physical pain were still in distress, and that the relief of suffering required attention to psychological, social, and spiritual dimensions alongside physical symptoms. The practical implication for GPs is that a consultation that focuses exclusively on opioid dose titration while ignoring the patient's fear of death, family distress, financial concerns, or loss of meaning will produce suboptimal pain control — because psychological distress amplifies the perception of physical pain through central sensitisation mechanisms and reduces the efficacy of analgesics. This is not merely philosophical: studies of cancer pain management consistently show that depression and anxiety are independently associated with higher pain scores and greater analgesic requirements, and that treating depression/anxiety in palliative patients reduces opioid dose requirements. The OPQRST mnemonic applied to palliative pain should include specific prompts for neuropathic features (burning, shooting, allodynia) and factors that modify pain (movement, position, time of day, emotional state) — these determine analgesic selection far more reliably than the cancer diagnosis alone. The Abbey Pain Scale for cognitively impaired palliative patients is an essential tool — it is observational rather than self-report, and captures pain through behavioural indicators (facial grimacing, moaning, restlessness, body posture, physiological changes). It is validated for use in dementia and delirium, both of which are common in palliative patients. GPs visiting palliative patients at home should carry the Abbey scale or have it accessible on their smartphone — unrecognised pain in cognitively impaired palliative patients is a significant quality care issue.

The WHO analgesic ladder Step 2 controversy is clinically important — the traditional model of codeine or tramadol as a mandatory intermediate step is increasingly questioned in palliative medicine, primarily because: (1) codeine's variable CYP2D6 metabolism means it is either ineffective (poor metabolisers — 7% of Northern Europeans) or toxic (ultra-rapid metabolisers — 1–2%); (2) tramadol has significant drug interactions (serotonin syndrome with SSRIs/SNRIs/TCAs, seizure lowering, serotonin toxicity) that are particularly problematic in palliative patients on multiple psychotropic drugs; (3) multiple RCTs have shown that low-dose Step 3 opioids (oral morphine 5–10 mg QDS) are more effective and better tolerated than maximum-dose Step 2 opioids. Current NICE guidance on cancer pain (NG151, 2021) recommends that clinicians should consider moving directly from Step 1 to low-dose Step 3 if Step 1 is inadequate. The opioid conversion table is the most practically useful piece of pharmacological knowledge in palliative primary care — GPs should have access to these conversion ratios (memorised or via the 'Palliative Drugs' app — a free, excellent palliative pharmacology reference) because they are needed: when switching routes (patient unable to swallow → SC infusion), when switching opioid (morphine toxicity → oxycodone or fentanyl), and when prescribing breakthrough doses (PRN dose = 1/6 of total 24-hour opioid dose). The 25–30% reduction on opioid rotation accounts for incomplete cross-tolerance — different opioids have partially different receptor binding profiles, meaning tolerance to one opioid does not fully transfer to another. Starting at 100% of the calculated equivalent dose when rotating opioids risks overdose.

Single-fraction radiotherapy (SFRT) at 8 Gy for painful bone metastases is the most evidence-based, underused intervention in UK palliative primary care — a Cochrane meta-analysis of 25 RCTs (Chow et al. 2007, updated 2012) showed that single-fraction 8 Gy is equally effective to multi-fraction regimens (e.g., 20 Gy in 5 fractions) for pain control, with equivalent complete response rate (approximately 25%) and partial response rate (approximately 50%), NNT approximately 4 for significant pain relief. Single-fraction treatment is obviously more convenient (one visit to the radiotherapy department vs five) and has equivalent side effects. The barrier to use is that GPs often do not know this option exists, or feel it requires a complex oncology referral process. In fact, in most UK cancer centres, a telephone call to the oncology team describing a patient with known bone metastases and localised pain allows arrangement of palliative radiotherapy within 1–2 weeks. Lidocaine 5% medicated plasters (Versatis) are licensed in the UK for post-herpetic neuralgia but are widely used off-label in palliative care for localised neuropathic pain — particularly post-thoracotomy pain, intercostal nerve infiltration from mesothelioma or rib metastases, and post-mastectomy pain syndrome. The mechanism is direct sodium channel blockade at the application site, providing topical analgesia without systemic absorption. They are applied for 12 hours then removed for 12 hours (to prevent tolerance). Each plaster covers approximately 10 × 14 cm — multiple can be used if the pain area is larger. They are excellent for patients who cannot tolerate further systemic analgesic dose increases due to side effects.

The Gold Standards Framework (GSF) is the UK primary care framework for proactive identification and management of patients approaching end of life — it recommends that all palliative patients are: (1) identified on a practice GSF/palliative care register (usually discussed at monthly MDT meetings); (2) assessed using the 'surprise question' ('Would I be surprised if this patient died in the next 12 months?'); (3) have their needs documented using the 3 Cs: Coding (prognostic), Communication (advance care planning conversations), and Co-ordination (OOH notification, DNACPR, EPS prescribing). The GSF has been shown to significantly reduce emergency admissions in the last weeks of life, increase the proportion of patients who die in their preferred place, and improve quality of the dying process. Every palliative patient in a GP practice should be on the GSF register. Coeliac plexus block for pancreatic cancer pain is one of the most effective interventional analgesic procedures available — it provides significant pain reduction in 70–80% of patients with pancreatic cancer abdominal pain and can dramatically reduce opioid requirements (and therefore opioid side effects) for months. It is performed under CT or ultrasound guidance, injecting phenol or absolute alcohol around the coeliac ganglia, destroying the pain afferents from the upper abdominal viscera. The procedure takes approximately 45 minutes under sedation. Despite its effectiveness, it is significantly underused — many patients with pancreatic cancer pain are maintained on escalating opioid doses with increasing toxicity when they could have had a coeliac plexus block. GPs who have patients with difficult-to-control upper abdominal cancer pain (especially pancreatic) should discuss this option with the palliative care or pain team.

The methylnaltrexone (Relistor) indication for refractory opioid-induced constipation is important to know — it is a peripherally-acting mu-opioid receptor antagonist that reverses opioid-induced gut motility impairment without crossing the blood-brain barrier (so it does not reduce analgesia or precipitate withdrawal). It is indicated when standard laxatives have failed in patients on stable opioid doses. Dose: 8 mg SC (body weight <62 kg) or 12 mg SC (≥62 kg) on alternate days. Response (bowel movement) typically occurs within 4 hours of injection. It is available on NHS prescription, and district nurses can administer it at home. The combination of diamorphine + midazolam + glycopyrronium in a 24-hour syringe driver is the standard UK anticipatory end-of-life prescription that GPs should be comfortable initiating or supporting — diamorphine provides pain control and reduces dyspnoea, midazolam reduces agitation and anxiety, and glycopyrronium reduces respiratory secretions (the 'death rattle' — noisy breathing from pharyngeal/bronchial secretions that distresses families even though it does not distress the patient). This combination can be prescribed in advance by the GP as part of anticipatory end-of-life prescribing (also called 'just in case' boxes or 'anticipatory medicines'), allowing district nurses and out-of-hours services to initiate and adjust the driver at home without needing a doctor present, dramatically reducing emergency hospital admissions in the last days of life. The prescription should be written when the patient is deteriorating but still at home, labelled clearly for 'if needed in the last days of life,' and the medications stored at the patient's home. Doses: diamorphine 10–20 mg/24hr (opioid-naïve — calculate from current opioid), midazolam 10 mg/24hr (standard starting), glycopyrronium 0.6–1.2 mg/24hr.

The evidence that opioids do not hasten death when used appropriately for dyspnoea in dying patients is important for GPs and families to understand — there is a widespread misconception (the 'doctrine of double effect' misapplication) that giving opioids to a dying patient causes earlier death. The evidence does not support this: multiple prospective studies of opioid use in the last days of life show no correlation between opioid dose (within therapeutic ranges) and time to death. Opioids titrated to symptom relief (not to unconsciousness) in the dying patient are ethical, compassionate, and clinically correct. The concern about 'hastening death' from appropriate palliative analgesia is one of the most common barriers to adequate symptom control in dying patients, and GPs must be prepared to address this clearly in family conversations. The clinical statement is: 'We are giving morphine to relieve the pain and breathlessness — at the doses we're using, the evidence shows this does not shorten life.' Haloperidol as the preferred antiemetic for palliative nausea is a key piece of prescribing knowledge — haloperidol acts on the chemoreceptor trigger zone (CTZ) via D2 receptor blockade and is the most effective single antiemetic for the most common types of palliative nausea (chemical/metabolic — from opioids, uraemia, hypercalcaemia). It is also effective at very low doses (0.5–1.5 mg OD or BD) and can be given SC, making it ideal for the palliative syringe driver. The antiemetic doses are much lower than the antipsychotic doses — GPs should not be concerned about using haloperidol 0.5 mg as an antiemetic in a palliative patient, which is 10–20-fold below the antipsychotic dose range.

DS1500 fast-tracking is one of the most practically important GP administrative tasks in palliative care — it is a form completed by the GP or specialist (takes approximately 5 minutes) that entitles patients with a terminal diagnosis and life expectancy of 12 months or less to fast-track access to PIP (Personal Independence Payment for under-65s) or Attendance Allowance (over-65s) without the need to attend an assessment or wait for the normal processing time (which can be months). The financial impact is substantial — Attendance Allowance at the higher rate is £108.55/week, and PIP enhanced daily living is £101.75/week. For a patient with months to live, this money makes a meaningful difference to quality of life and ability to afford care at home. GPs should routinely consider DS1500 at or near the time of a terminal diagnosis. The form is available from the DWP website and can be submitted electronically. Note that the DS1500 does not affect driving licence status (unlike some disability-related notifications) and does not need to be disclosed to the patient — the GP can submit it directly to DWP on the patient's behalf, or send it to the patient/family to submit. The 'hospice not only for the last days of life' message is important for GPs to communicate — a very common misconception among patients and families is that hospice admission means the person is about to die, or that accepting hospice care means 'giving up.' This leads to late referrals and patients not accessing excellent symptom control, social support, and day hospice services that could significantly improve quality of life for months. The correct framing is: 'The hospice is a centre of expertise for symptom management, support, and quality of life — patients come in for help managing symptoms and go home again. It's not about dying, it's about living as well as possible with your illness.'

The principle that anticipatory medicines (JIC prescriptions) must be updated when the regular opioid dose changes is a critical prescribing safety point that is frequently overlooked in community palliative care — the PRN breakthrough dose is always calculated as 1/6 of the total 24-hour opioid dose. If the regular MST dose increases from 30 mg BD to 60 mg BD (i.e., from 60 mg/day to 120 mg/day), the PRN Oramorph dose must be updated from 10 mg to 20 mg. If the anticipatory medicines in the JIC box still have the old PRN dose, district nurses administering the breakthrough may give inadequate analgesia. The practical solution is: every time the regular opioid dose is adjusted, immediately issue a new prescription for the updated PRN dose and communicate to the district nursing team. Some GP practices maintain a standing arrangement with their palliative care specialist team to co-manage JIC prescriptions and dose adjustments, which improves safety. Bereavement follow-up is a core primary care competency that is increasingly recognised as a clinical outcome of palliative care quality — the GP who provided care to the dying patient is often the most trusted and meaningful person to contact the bereaved carer in the weeks after death. A brief telephone call at 6 weeks after bereavement, or a condolence letter, costs very little time but has significant therapeutic value — it validates the carer's grief, provides an opportunity to identify complicated grief (prolonged grief disorder — NICE recognised as a clinical diagnosis since 2022), and maintains the therapeutic relationship that will be needed for the carer's own healthcare. GPs should ensure this follow-up is part of their standard palliative care pathway.